Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12770603 | 1.00 | TSHR (0.39) | TSHRTAAR1PDE4DSLC6A2ALDH1A1 | |
| SCHEMBL10978460 | 0.89 | TSHR (0.48) | TSHRTAAR1SLC6A2ALDH1A1LMNA | |
| SCHEMBL10978467 | 0.89 | TSHR (0.48) | TSHRTAAR1SLC6A2ALDH1A1LMNA | |
| SCHEMBL14655081 | 0.88 | SLC6A2 (0.44) | TSHRTAAR1PDE4DSLC6A2ALDH1A1 | |
| SCHEMBL291876 | 0.88 | SLC6A2 (0.44) | TSHRTAAR1PDE4DSLC6A2ALDH1A1 | |
| SCHEMBL10755388 | 0.88 | SLC6A2 (0.44) | TSHRTAAR1PDE4DSLC6A2ALDH1A1 | |
| SCHEMBL15892809 | 0.88 | TSHR (0.47) | TSHRTAAR1SLC6A2ALDH1A1LMNA | |
| SCHEMBL15892812 | 0.88 | TSHR (0.47) | TSHRTAAR1SLC6A2ALDH1A1LMNA | |
| SCHEMBL12552580 | 0.87 | TSHR (0.40) | TSHRTAAR1PDE4DSLC6A2ALDH1A1 | |
| SCHEMBL15150364 | 0.87 | TSHR (0.40) | TSHRTAAR1PDE4DSLC6A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130196987-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | EISAI CO., LTD. (JP) | 2013-08-01 | — | — | US | disclosed |
| US-8329742-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-7799827-B2 | Macrocyclic compounds useful as pharmaceuticals | EISAI CO., LTD. (JP) | 2010-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196987-A1 | MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS | FLT4, VEGFA, FLT1 | TSHR 1244/4885TAAR1 4612/4885PDE4D 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.